IMO REGN looks like a high quality research outfit (lots of papers in high quality journals). As an example, here is a link a recent paper in Nature (Note: that Genentech has similar research in the same issue).
However, the CNTF failure made me question REGN. They found a high percentage of neutralizing antibodies to CNTF in a phase III trial (pleasse correct me if I am wrong). It would seem to me that when you are running a trial on a recombinant protein one of the first things that you want to look for are neutralizing antibodies. I just don't see how they could have missed this in the Phase I and II trials.
Neutralizing antibodies could be an issue with their VEGF trap, a non-native fusion protein.
I don't short stocks, but the current price seems expensive to me. If it were to fall below $10, I would consider a purchase of REGN.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.